Welcome to Prism!

Upload scholarly work, create communities, get citable links and more. To get the most out of Prism, log in with your NetID and check out our guide.

Published February 2021 | Version v1.0.0
Journal Article Open

COVID-19 vaccine-associated anaphylaxis: A statement of the World Allergy Organization Anaphylaxis Committee

  • 1. ROR icon Imperial College London
  • 2. Hospital Quironsalud Bizkaia
  • 3. ROR icon University of Sydney
  • 4. ROR icon Vall d'Hebron Hospital Universitari
  • 5. ROR icon National Sagamihara Hospital
  • 6. ROR icon Ain Shams University
  • 7. ROR icon Emory University
  • 8. ROR icon Mayo Clinic
  • 9. ROR icon Northwestern University
  • 10. ROR icon Chinese University of Hong Kong
  • 11. ROR icon University of Cape Town
  • 12. ROR icon University of Padua
  • 13. ROR icon Centro Médico Docente La Trinidad
  • 14. ROR icon University of Verona
  • 15. ROR icon Hospital Sírio-Libanês
  • 16. ROR icon Tan Tock Seng Hospital
  • 17. ROR icon Charité - University Medicine Berlin

Abstract

Vaccines against COVID-19 (and its emerging variants) are an essential global intervention to control the current pandemic situation. Vaccines often cause adverse events; however, the vast majority of adverse events following immunization (AEFI) are a consequence of the vaccine stimulating a protective immune response, and not allergic in etiology. Anaphylaxis as an AEFI is uncommon, occurring at a rate of less than 1 per million doses for most vaccines. However, within the first days of initiating mass vaccination with the Pfizer-BioNTech COVID-19 vaccine BNT162b2, there were reports of anaphylaxis from the United Kingdom and United States. More recent data imply an incidence of anaphylaxis closer to 1:200,000 doses with respect to the Pfizer-BioNTech vaccine. In this position paper, we discuss the background to reactions to the current COVID-19 vaccines and relevant steps to mitigate against the risk of anaphylaxis as an AEFI. We propose a global surveillance strategy led by allergists in order to understand the potential risk and generate data to inform evidence-based guidance, and thus provide reassurance to public health bodies and members of the public.

Other

original_citation: Turner PJ, Ansotegui IJ, Campbell DE, Cardona V, Ebisawa M, El-Gamal Y, Fineman S, Geller M, Gonzalez-Estrada A, Greenberger PA, Leung ASY, Levin ME, Muraro A, Borges MS, Senna G, Tanno LK, Thong BYH, Worm M, Comm WAOA. COVID-19 vaccine-associated anaphylaxis: A statement of the World Allergy Organization Anaphylaxis Committee. World Allergy Organization Journal. 2021;14(2):10.

Acknowledgements

We thank Drs Sophie Farooque and Alessia Baseggio Conrado (London) for reviewing a draft of this manuscript.

Files

COVID-19 vaccine-associated anaphylaxis.pdf
Files (1.0 MB)
Name Size Download all
md5:e22b08bbd1567b944402ca635e8a7a5d
1.0 MB Preview Download

Additional details

Created:
March 30, 2023
Modified:
September 19, 2023